Generic and biosimilar medicines saved U.S. patients $3.6 trillion in the last decade. Learn how this industry is driving America Forward as a force for healthcare stability and economic resilience.
Quick Links:
GRx+Biosims 2026 brought FDA leaders together with manufacturers, policy experts, and supply chain partners.
AAM highlights the key role generic medicines manufacturers are playing in ramping up the supply of estrogen patches.
Desi’s journey from painful swelling to playing soccer again shows the power of accessible medicines.
Learn how a biosimilar medication helped Eileen stay focused on auditions, not Crohn’s disease.
Generic and biosimilar medicines are a driving force of safety, strength and security in America. These medicines make it possible for patients and communities to thrive.
